Luisa Circelli

Dr. Luisa Circelli

AMES-Centro Polidiagnostico Strumentale srl, via Padre Carmine Fico, 24, Casalnuovo di Napoli, Naples, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
AOAlessandro Ottaiano
Alessandro Ottaiano
Michele CaragliaMichele Caraglia
Michele Caraglia
Annabella Di MauroAnnabella Di Mauro
Annabella Di Mauro
GGerardo Botti
Gerardo Botti
AAngela Lombardi
Angela Lombardi
GNGuglielmo Nasti
Guglielmo Nasti
Genetic dynamics underlying cancer progression are largely unknown and several genes involved in highly prevalent illnesses (e.g., hypertension, obesity, and diabetes) strongly concur to cancer phenotype heterogeneity. To study genotype-phenotype relationships contributing to the mutational evolution of colorectal cancer (CRC) with a focus on liver metastases, we performed genome profiling on tumor tissues of CRC patients with liver metastatic disease and no co-morbidities. We studied 523 cancer-related genes and tumor-immune microenvironment characteristics in primary and matched metastatic tissues. We observed a loss of KRAS and SMAD4 alterations and a high granzyme-B+ T-cell infiltration when the disease did not progress. Conversely, gain in KRAS, PIK3CA and SMAD4 alterations and scarce granzyme-B+ T-cells infiltration were observed when the tumor evolved towards a poly-metastatic spread. These findings provide novel insights into the identification of tumor oligo-metastatic status, indicating that some genes are on a boundary line between these two clinical settings (oligo- vs. poly-metastatic CRC). We speculate that the identification of these genes and modification of their evolution could be a new approach for anti-cancer therapeutic strategies.

24 April 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
AOAlessandro Ottaiano
Alessandro Ottaiano
LCLuisa Circelli
Luisa Circelli
ALAngela Lombardi
Angela Lombardi
SSStefania Scala
Stefania Scala
NMNicola Martucci
Nicola Martucci
GNGuglielmo Nasti
Guglielmo Nasti
Genetics and immunologic dynamics pushing the evolution of colorectal cancer (CRC) from the primary tumor to the metastases are largely unknown; cancer heterogeneity makes challenging both therapy and mechanistic studies. We selected patients developing CRC with lung-limited metastatic disease as only illness during their life in order to find any relevant genotype–phenotype relationship. Analysis of 523 cancer-relevant genes and of immune cells infiltration in primary and metastatic tissues revealed atypical genomic trajectories (TMB decrease, KRAS and SMAD4 regressive mutations), specific genetic events (ERBB2 point mutations) and scarce T-cell infiltration. These insights provide novel information in oligometastatic CRC biology and new perspectives for cancer monitoring and anti-cancer therapeutic strategies.

23 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AOAlessandro Ottaiano
Alessandro Ottaiano
APAngela Petito
Angela Petito
MSMariachiara Santorsola
Mariachiara Santorsola
VGvalerio gigantino
valerio gigantino
MCMaurizio Capuozzo
Maurizio Capuozzo
PMPaolo Muto
Paolo Muto
Background: in recent years, the management of advanced colorectal cancer (CRC) has been greatly improved with integrated strategies including stereotactic radiation therapy (SRT). The administration of SRT has been demonstrated, particularly in oligo-metastatic (om) CRC, to be a safe and effective option. Interestingly, it has been demonstrated that SRT can induce regression of tumors in non-irradiated regions (“abscopal effect”) through stimulation of anti-tumor immune effects (“radiation-induced immunity”). We have recently shown that lung-limited omCRC is characterized by regression of tumor clones bearing specific key driver gene mutations. Aims: to assess the genetic evolution on tumor cancer cells induced by SRT in lung-limited omCRC. Secondary objectives included descriptions of the abscopal effect, responses’ duration, toxicity, and progression-free survival. A translational research will be performed to evaluate tumor genetic evolution (through liquid biopsies and Next Generation Sequencing), HLA class I repertoire, peripheral immune cells, and cytokine dynamics. Methods: PRELUDE-1 is a prospective translational study. SRT will be administered only to the largest nodule (with a maximum diameter ≤ 25 mm) in omCRC with two or three radiologically evident lesions. The sample size is based on the innovative hypothesis that radiation-induced immunity could induce regression of tumor clones bearing KRAS oncogene mutations. According to the binomial test, considering the frequency of KRAS mutations and assuming a probability of mutant KRAS→wild type KRAS of p0 = 0.0077, with α = 0.05 and 1-β = 0.60, the final sample size is 25 patients.

27 August 2021 in Genes
Verified
Journal Article
Open access
PDF file
LRLuca Rocchetti
Luca Rocchetti
EEEvangelista Eloisa
Evangelista Eloisa
LFLuigia De Falco
Luigia De Falco
LCLuisa Circelli
Luisa Circelli
PSPasquale Savarese
Pasquale Savarese
AFAntonio Fico
Antonio Fico
X-linked intellectual deficiency (XLID) is a widely heterogeneous group of genetic disorders that involves more than 100 genes. The mediator of RNA polymerase II subunit 12 (MED12) is involved in the regulation of the majority of RNA polymerase II-dependent genes and has been shown to cause several forms of XLID, including Opitz-Kaveggia syndrome also known as FG syndrome (MIM #305450), Lujan-Fryns syndrome (MIM #309520) and the X-linked Ohdo syndrome (MIM #300895). Here, we report on two first cousins with X-linked Ohdo syndrome with a missense mutation in MED12 gene, identified through whole exome sequencing. The probands had facial features typical of X-linked Ohdo syndrome, including blepharophimosis, ptosis, a round face with a characteristic nose and a narrow mouth. Nextera DNA Exome kit (Illumina Inc., San Diego, CA, USA) was used for exome capture. The variant identified was a c.887G > A substitution in exon 7 of the MED12 gene leading to the substitution of a glutamine for a highly conserved arginine (p. Arg296Gln). Although the variant described has been previously reported in the literature, our study contributes to the expanding phenotypic spectrum of MED12-related disorders and above all, it demonstrates the phenotypic variability among different affected patients despite harboring identical mutations.

Verified
Journal Article
Open access
PDF file
ARandrea ronchi
andrea ronchi
PVPaola Vitiello
Paola Vitiello
GDGiuseppe D'Abbronzo
Giuseppe D'Abbronzo
SCStefano Caccavale
Stefano Caccavale
Giuseppe ArgenzianoGiuseppe Argenziano
Giuseppe Argenziano
RFRenato Franco
Renato Franco
Most primary cutaneous lymphomas consist of T-cell lymphomas or small cell lymphomas; however, the skin may also be affected by lymphomas with large cell morphology, as a primary or secondary localization. A minority of cases consist of primary cutaneous B-cell lymphomas (PCBCLs). PCBCLs are a heterogeneous group of rare neoplasms with an overlapping morphological and immunohistochemical picture of the different subtypes. Nevertheless, differential diagnosis in the setting of this group of neoplasms is mandatory to identify the correct therapy and prognosis, but it may be challenging since, due to the rarity of these neoplasms, they may not always be familiar to pathologists. Indeed, immunohistochemistry may not be enough to distinguish the different histotypes, which overlap in immunohistochemical features. Furthermore, the ever-increasing knowledge of the molecular features of systemic B-cell lymphomas, such as gene rearrangements with clinical significance, has led in recent years to further investigation into the molecular landscape of PCBCLs with large cell morphology. This work aimed to provide a practical diagnostic guide for pathologists dealing with primary cutaneous large B-cell lymphomas.

20 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
AOAlessandro Ottaiano
Alessandro Ottaiano
LCLuisa Circelli
Luisa Circelli
MSMariachiara Santorsola
Mariachiara Santorsola
Michele CaragliaMichele Caraglia
Michele Caraglia
We extend our appreciation to the authors who have made substantial contributions to the Special Issue focusing on “Colorectal Cancer Metastasis”